Regorafenib
GRID
Bayer · Phase 3 · Completed · Enrollment 199
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Regorafenib 160 mg, 3 weeks on 1 off | GIST after imatinib and sunitinib | 160 mg | ITT | placebo | median progression-free survival: 4.8 months, primary analysisprogression-free survival hazard ratio vs placebo: 0.27 HR, primary analysismedian overall survival: 17.4 months, final OS analysis, 162 events |
| Placebo | GIST after imatinib and sunitinib | placebo | ITT | n/r | median progression-free survival: 0.9 months, primary analysismedian overall survival: 17.4 months, final OS analysis; 88% crossed over |